Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Digital nurse companion: could an app ease the burden of chronic illness?

NCT ID NCT05750953

Symptom relief Sponsor: University of Stavanger Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial tests a nurse-assisted eHealth program for patients with heart failure or colorectal cancer. After leaving the hospital, participants use a tablet with the MyDignio app to track vital signs and symptoms, and communicate with a nurse navigator. The goal is to see if this support boosts patients' confidence in managing their condition and improves their experience with treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A nurse-assisted eHealth intervention using a tablet with the MyDignio app and Bluetooth monitoring devices for daily vital signs and symptom tracking.
What this could lead to
If effective, this approach could improve patients' confidence and ability to manage chronic conditions at home, potentially reducing hospital readmissions and improving quality of life.
What could go wrong
The trial is relatively small and focuses on short-term outcomes, so benefits may not be lasting or generalizable. Some patients may find the technology difficult to use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

204 people

The number who actually took part.

Started

May 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All participants: symptomatic HF or surgically treated for either colon or rectal cancer (Colon-Rectal Cancer Duke's class 1-3, curative), able to speak and write Norwegian Exclusion Criteria: * Heart failure population: patient is on a waiting list for a heart transplant, requires a Left Assist Ventricular Device (LVAD), and has a life expectancy \<6 months * Colon-rectal cancer population: metastatic cancer, Surgical Complication Score \> 3, and acute medical crisis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colon cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm colorectal cancer heart failure Noncommunicable Diseases rectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colon rectal cancer Heart failure Non communicable diseases

Contacts and locations

Locations

  • Anne Marie Lunde Husebø

    Stavanger, Rogaland, 4036, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.